ライフサイエンスコーパス: osteoporotic

1 ne loss, while gain-of-function animals were osteoporotic.

2 clinical data concerning the effects of anti-osteoporotic agents on bone properties.

3 y B-cell knockout (KO) mice were found to be osteoporotic and deficient in BM OPG, phenomena rescued

4 Decreases in the risk of osteoporotic and hip fractures during 1 to 10 years of b

5 y secondary to an interaction of traditional osteoporotic and HIV-specific risk factors, and possibly

6 g of the physicochemical differences between osteoporotic and normal conditions will facilitate the d

7 nalysis on a gene expression data of normal, osteoporotic and osteomyelitis bone conditions.

8 e-targeting system prevented bone loss in an osteoporotic animal model.

9 en bone density decreases as demonstrated in osteoporotic animal models.

10 patients with normal BMD at baseline became osteoporotic at 5 years.

11 995 g/cm(2), and 18 patients (45%) showed an osteoporotic BMD (T score less than -2.5) of at least tw

12 ent, namely a fragility fracture, or with an osteoporotic BMD should also be treated.

13 Most interestingly, we show that osteoporotic bone cells experience similar or higher max

14 s in vivo, and the mechanical environment of osteoporotic bone cells is not known.

15 easy to use radiofrequency device to detect osteoporotic bone conditions.

16 Osteoporotic bone fracture rates are highest in countrie

17 osteocytes and osteoblasts from healthy and osteoporotic bone in a rat model of osteoporosis.

18 maintains bone formation, thereby preventing osteoporotic bone loss induced by ovariectomy in adult m

19 ne resorptive capacity, corroborated with an osteoporotic bone phenotype in the Galpha(13)(DeltaM/Del

20 difference between bone cells in healthy and osteoporotic bone.

21 Osteoporotic bones have reduced spongy bone mass, altere

22 ific conditional S1P(1) knockout mice showed osteoporotic changes due to increased osteoclast attachm

23 and pain-related disability associated with osteoporotic compression fractures in patients treated w

24 as established to mimic human postmenopausal osteoporotic conditions under nutrient deficiency.

25 ificantly differentially-expressed among non-osteoporotic controls, osteopenia and osteoporosis patie

26 disease) and 53 age- and gender-matched non-osteoporotic controls.

27 influence new bone formation in a 3 mm femur osteoporotic defect model in ovariectomized rats.

28 ased bone formation, and caused a subsequent osteoporotic deficit, including decreased trabecular bon

29 mation of hyperresorptive OCs and preventing osteoporotic deficits.

30 search to better inform the long-term use of osteoporotic drug therapies is delineated.

31 omen who were currently on prescription anti-osteoporotic drugs and any individuals deemed to be unsu

32 del may serve as a suitable tool to evaluate osteoporotic drugs and new biomaterials or fracture impl

33 these post-menopausal women not yet on anti-osteoporotic drugs.

34 f marrow cavities, liver avoidance, and anti-osteoporotic effects.

35 ysis, we showed that GPR40(-/-) mice exhibit osteoporotic features suggesting a positive role of GPR4

36 ing lithium chloride in Runx2-overexpressing osteoporotic female mice rescued the Wnt/beta-catenin si

37 ram for postmenopausal females, particularly osteoporotic females, who are at greater risk of tooth l

38 Osteoporotic fracture (11.9%) was also more common in cl

39 THR patients who had experienced a previous osteoporotic fracture (HR 0.48, 95% CI 0.23-0.99).

40 [HR], 1.43 [95% CI, 1.16 to 1.78]) and major osteoporotic fracture (HR, 1.21 [95% CI, 1.01 to 1.45])

41 the highest tertile had a lower risk of any osteoporotic fracture (HR: 0.65; 95% CI: 0.47, 0.88), ma

42 acture (HR: 0.65; 95% CI: 0.47, 0.88), major osteoporotic fracture (HR: 0.66; 95% CI: 0.45, 0.95), an

43 iated with a 30% decrease in the risk of any osteoporotic fracture (HR: 0.70; 95% CI: 0.50, 0.96).

44 n descent can help improve the prediction of osteoporotic fracture (OF) risk and BMD in Chinese popul

45 The decreased risks seen for osteoporotic fracture and colorectal cancer were outweig

46 ted whether MI constitutes a risk factor for osteoporotic fracture and examined secular trends in thi

47 erved for higher intake of flavonols for any osteoporotic fracture and major osteoporotic fracture, a

48 xists between individuals who are at risk of osteoporotic fracture and those who are receiving therap

49 Traits contributing to osteoporotic fracture are highly heritable, indicating t

50 ably, bone mineral density, osteoporosis and osteoporotic fracture are highly heritable; however, det

51 rea under the curve (AUC) for incident major osteoporotic fracture discrimination (AUC: FRAX with BMD

52 ars or older, who have been hospitalized for osteoporotic fracture from 2003 until 2005.

53 to LMWH) in 0.11% (95% CI, 0.02%-0.32%), and osteoporotic fracture in 0.04% (95% CI, < 0.01%-0.20%) o

54 ncreasing evidence suggests that the risk of osteoporotic fracture in adulthood could be determined p

55 risk factors for low bone mineral density or osteoporotic fracture in men or comparing 2 different me

56 eveloping strategies to reduce the burden of osteoporotic fracture in the population.

57 ead to longlasting reductions in the risk of osteoporotic fracture in their offspring.

58 B-12 and folic acid supplementation reduces osteoporotic fracture incidence in hyperhomocysteinemic

59 folic acid supplementation had no effect on osteoporotic fracture incidence in this elderly populati

60 roup analyses suggest a beneficial effect on osteoporotic fracture prevention in compliant persons ag

61 kshop: Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention to assess the available

62 Incidence of osteoporotic fracture requiring hospitalization was dete

63 or modulator) have each been shown to reduce osteoporotic fracture risk among men receiving androgen-

64 drugs available for these diseases, reducing osteoporotic fracture risk by 50-60% in persons with low

65 Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to m

66 concentrations may be associated with lower osteoporotic fracture risk in older adults, particularly

67 sorders and psychotropic medication use with osteoporotic fracture risk in routine clinical practice.

68 The observed 10-year major osteoporotic fracture risk of 6.3% (95% CI, 3.4-9.2%) wa

69 ersons aged >80 y, in per-protocol analyses, osteoporotic fracture risk was lower in the intervention

70 Osteoporotic fracture risk was not significantly differe

71 Research shows that optimal screening for osteoporotic fracture risk will require risk factor info

72 hly heritable trait and a key determinant of osteoporotic fracture risk, but the genes responsible ar

73 as a clinical aid to assess an individual's osteoporotic fracture risk, with or without bone mineral

74 n in early life, midlife, and late life with osteoporotic fracture risk.

75 n, vitamin D and calcium deficiency increase osteoporotic fracture risk.

76 bone remodeling associated with an increased osteoporotic fracture risk.

77 proves bone mineral density, a surrogate for osteoporotic fracture risk.

78 e important dietary components that modulate osteoporotic fracture risk.

79 etic component and an important predictor of osteoporotic fracture risk.

80 men with DM; HRs for 1-unit increase in FRAX osteoporotic fracture score, 1.04; 95% CI, 1.02-1.05, fo

81 Major osteoporotic fracture scores showed significant fracture

82 higher among those with osteomyelitis at all osteoporotic fracture sites after adjusting for key rela

83 Risk of hip or major osteoporotic fracture through 2009 or 12 years following

84 Tool score, or FRAX), 10-year risk for major osteoporotic fracture was greater than 20% (FRAX), quant

85 Following an osteoporotic fracture, a multidisciplinary rehabilitatio

86 vity, prolonged corticosteroid use, previous osteoporotic fracture, and androgen deprivation therapy.

87 omen; 212 (17.8%) were identified as a major osteoporotic fracture, and of these, 129 (10.9%) were a

88 0-60% in persons with low bone mass or prior osteoporotic fracture, and SREs by one-third in cancer p

89 Outcomes were hip fracture, major osteoporotic fracture, any fracture, initiation of osteo

90 nols for any osteoporotic fracture and major osteoporotic fracture, as well as flavones for hip fract

91 Outcome measures were time to osteoporotic fracture, overall and by anatomic site, and

92 For those patients with substantial risk of osteoporotic fracture, the clinician should obtain a bon

93 d of sound (SOS)-a heritable risk factor for osteoporotic fracture-can identify low-risk individuals

94 ccurately identify those at greatest risk of osteoporotic fracture.

95 The primary endpoint was time to first osteoporotic fracture.

96 rs) after cohort entry for an incident major osteoporotic fracture.

97 ral density (BMD) predicts the likelihood of osteoporotic fracture.

98 up, 21 (4.6%) recipients experienced a major osteoporotic fracture.

99 ure and 113 participants experienced a major osteoporotic fracture.

100 fully improve the prediction of hip or major osteoporotic fracture.

101 ty and an increased risk of fracture, termed osteoporotic fracture.

102 nd may remain an option in the prevention of osteoporotic fracture.

103 a means to improve bone strength and reduce osteoporotic fracture.

104 oteins increase the risk of osteoporosis and osteoporotic fracture.

105 Vertebral fractures are the most common osteoporotic fracture.

106 d bone mineral density and increased risk of osteoporotic fracture.

107 to maximize efficacy in patients at risk for osteoporotic fracture.

108 ross-linking, thereby increasing the risk of osteoporotic fracture.

109 ed to low bone density and increased risk of osteoporotic fracture.

110 strong diagnostic value for osteoporosis and osteoporotic fracture.

111 % for hip fracture or at least 20% for major osteoporotic fracture.

112 lomipramine (CLP), have an increased risk of osteoporotic fracture.

113 This study [B-vitamins for the PRevention Of Osteoporotic Fractures (B-PROOF)] aimed to determine whe

114 an age = 79 years) in the Caregiver-Study of Osteoporotic Fractures (Caregiver-SOF) (1999-2009), an a

115 tio [HR]: 0.85; 95% CI: 0.74 to 0.97), major osteoporotic fractures (HR: 0.85; 95% CI: 0.72 to 0.99),

116 Incident nontraumatic major osteoporotic fractures (MOFs) and hip fractures.

117 femoral neck) and an increased risk of both osteoporotic fractures (odds ratio [OR] 1.3, 95% CI 1.09

118 e of both risk alleles increased the risk of osteoporotic fractures (OR 1.3, 1.08-1.63, p=0.006) and

119 y community-dwelling women from the Study of Osteoporotic Fractures (SOF) cohort (mean age 83 years)

120 The Study of Osteoporotic Fractures (SOF) is a prospective, observati

121 Pittsburgh Clinical Center for the Study of Osteoporotic Fractures (SOF), a prospective cohort study

122 99-2009), an ancillary study to the Study of Osteoporotic Fractures (SOF).

123 with adjudicated fracture outcomes (Study of Osteoporotic Fractures [December 1998-July 2008]; Osteop

124 mitigating bone loss and in reducing risk of osteoporotic fractures among older adults.

125 amined magnesium intake as a risk factor for osteoporotic fractures and altered bone mineral density

126 (>3 years) use of drug therapies to prevent osteoporotic fractures and identify research gaps and ne

127 Osteoporotic fractures and osteoporosis were found in 37

128 e-related disorder leading to an increase in osteoporotic fractures and resulting in significant suff

129 T to assess performance for predicting major osteoporotic fractures and to compare with the Fracture

130 Osteoporotic fractures are a leading cause of disability

131 Although methods to identify risk for osteoporotic fractures are available and medications to

132 Osteoporotic fractures are common among elderly men.

133 at BPs dispensed for secondary prevention of osteoporotic fractures are not associated with increased

134 an women, age >/=65 years, from the Study of Osteoporotic Fractures cohort was performed.

135 min K antagonists (VKAs) are at high risk of osteoporotic fractures compared with the background popu

136 ssociated with a significantly lower risk of osteoporotic fractures compared with VKA.

137 with nonmetastatic cancer may be at risk for osteoporotic fractures due to baseline risks or due to t

138 The Study of Osteoporotic Fractures followed up 8022 women for 9.1 ye

139 udies, the Beijing OA Study and the Study of Osteoporotic Fractures from the US.

140 1.6 years), with documented subsequent major osteoporotic fractures in 7.4% (n = 686), including hip

141 The aims are to establish the prevalence of osteoporotic fractures in ISM and to investigate the ass

142 ncluded 517 men who were participants in the Osteoporotic Fractures in Men (MrOS) Study (>=65 y of ag

143 ation-based age-specific fracture rates; the Osteoporotic Fractures in Men (MrOS) study and published

144 n Older Men Study (an ancillary study to the Osteoporotic Fractures in Men (MrOS) Study conducted in

145 The Osteoporotic Fractures in Men (MrOS) study is the first

146 porotic Fractures [December 1998-July 2008]; Osteoporotic Fractures in Men Study [March 2000-March 20

147 The Osteoporotic Fractures in Men Study followed up 5995 men

148 d DHEA-S in the prospective population-based Osteoporotic Fractures in Men study in Sweden (2,416 men

149 In a cohort of 1,104 elderly men from the Osteoporotic Fractures in Men Study, 25(OH)D serum level

150 sical performance with incident falls in the Osteoporotic Fractures in Men Study, a large prospective

151 study of 2,865 participants derived from the Osteoporotic Fractures in Men Study, a prospective multi

152 >/=65 years of age who were enrolled in the Osteoporotic Fractures in Men Study.

153 Participants were recruited from the Osteoporotic Fractures in Men Study.

154 to osteoporosis and to estimate the risk of osteoporotic fractures in relation to body weight, lean

155 The number of osteoporotic fractures in the groups was similar.

156 Participants in the Study of Osteoporotic Fractures in whom pelvic radiographs had be

157 past decades, the association between MI and osteoporotic fractures increased steadily.

158 assessed at the baseline Caregiver-Study of Osteoporotic Fractures interview, conducted in 1999-2001

159 in patients with ISM shows that the risk of osteoporotic fractures is high, especially in men.

160 ssary component of bone, but its relation to osteoporotic fractures is unclear.

161 Osteoporotic fractures occurred in 61 persons (4.2%) in

162 Only osteoporotic fractures of the hip, vertebrae, and wrist

163 Osteoporotic fractures present a significant social and

164 01 elderly women from the Caregiver-Study of Osteoporotic Fractures sample.

165 five families with X-linked osteoporosis and osteoporotic fractures that we report here.

166 The risk of osteoporotic fractures was evaluated among patients with

167 nationwide population, the absolute risk of osteoporotic fractures was low among patients with atria

168 Osteoporotic fractures were determined from medical reco

169 Over 10 y of follow-up, osteoporotic fractures were identified in 288 (24.2%) wo

170 We studied 5,839 women from the Study of Osteoporotic Fractures who had had serial pelvic radiogr

171 Reducing osteoporotic fractures will require more effective appro

172 ith AFFs to those from patients with typical osteoporotic fractures with and without bisphosphonate t

173 association between the replicated SNPs and osteoporotic fractures with data from two studies.

174 > or =74 years participating in the Study of Osteoporotic Fractures year 10 follow-up (n = 906) in 19

175 52 patients were reviewed (121 patients with osteoporotic fractures, 30 with malignant disease, and o

176 ls, among 6,653 participants in the Study of Osteoporotic Fractures, a community-based, prospective c

177 linical centers and enrolled in the Study of Osteoporotic Fractures, a longitudinal cohort study.

178 ncer risk factors, clinical risk factors for osteoporotic fractures, and bone mineral density surveil

179 D) is highly heritable, a major predictor of osteoporotic fractures, and has been previously associat

180 ted proton pump inhibitor (PPI) therapy with osteoporotic fractures, but it is not clear if PPIs dire

181 ing health outcomes, including prevention of osteoporotic fractures, is essential for promoting the w

182 aging needs to be used to diagnose prevalent osteoporotic fractures, such as spine fractures on chest

183 Despite African Americans' reduced risk of osteoporotic fractures, such fractures remain an importa

184 that many agents are effective in preventing osteoporotic fractures, the data are insufficient to det

185 Ps in the setting of secondary prevention of osteoporotic fractures.

186 ysteine concentrations are a risk factor for osteoporotic fractures.

187 but also to contribute to the development of osteoporotic fractures.

188 frican-American participants in the Study of Osteoporotic Fractures.

189 associated with a 4-fold increased risk for osteoporotic fractures.

190 hniques should be used to diagnose prevalent osteoporotic fractures.

191 1 older US women from the Caregiver-Study of Osteoporotic Fractures.

192 and April 2004 in a substudy of the Study of Osteoporotic Fractures.

193 n is the root cause for bone loss leading to osteoporotic fractures.

194 osphonates are effective in reducing hip and osteoporotic fractures.

195 eric femur that are infrequently affected by osteoporotic fractures.

196 d the exercise type most effective to reduce osteoporotic fractures.

197 tive was to examine FA intake in relation to osteoporotic fractures.

198 wered hip BMD but did not change the risk of osteoporotic fractures.

199 core for presymptomatic prediction of future osteoporotic fractures.

200 tate cancer is associated with bone loss and osteoporotic fractures.

201 ars of age who were enrolled in the Study of Osteoporotic Fractures.

202 independent risk factor for osteoporosis and osteoporotic fractures.

203 Patients with RA are at increased risk of osteoporotic fractures.

204 or =65 years of age enrolled in the Study of Osteoporotic Fractures.

205 of the hip in elderly women in the Study of Osteoporotic Fractures.

206 at the baseline examination of the Study of Osteoporotic Fractures.

207 at the baseline examination of the Study of Osteoporotic Fractures.

208 l anticoagulant (OAC) may affect the risk of osteoporotic fractures.

209 increased fracture risk, particularly major osteoporotic fractures.

210 om bisphosphonate-treated women with typical osteoporotic fractures.

211 t been systematically studied in relation to osteoporotic fractures.

212 gnificant gene BDNF was also associated with osteoporotic fractures.

213 hosphonates are a common treatment to reduce osteoporotic fractures.

214 c kidney disease, chronic liver disease, and osteoporotic fractures.

215 , and low risk of fractures [HR (95% CI) for osteoporotic fractures: 0.90 (0.83, 0.96); for hip fract

216 and high risk of fractures [HR (95% CI) for osteoporotic fractures: 1.08 (1.00, 1.06); for hip fract

217 1% of patients, respectively, and 60% of the osteoporotic group had > or = 1 abnormal metabolic bone

218 , the OR (95% CI) for the low, moderate, and osteoporotic groups were 2.66 (1.12 to 6.29), 2.31 (0.89

219 and 230% for those in the low, moderate, and osteoporotic groups, respectively.

220 tioxidant intake was associated with risk of osteoporotic hip fracture and whether this association w

221 t intake was associated with reduced risk of osteoporotic hip fracture in these elderly subjects, and

222 The role of antioxidant intake in osteoporotic hip fracture risk is uncertain and may be m

223 The primary outcome was the incidence of osteoporotic hip fracture, while secondary outcomes were

224 ified Cox regression comparing risk of major osteoporotic (hip, pelvis, spine, wrist, and proximal hu

225 fractures resulting from high trauma are not osteoporotic; however, this assumption has not been stud

226 y absorptiometry [DXA]) were normal, low, or osteoporotic in 24%, 55%, and 21% of patients, respectiv

227 uitment and protected bone integrity against osteoporotic insult.

228 hese results support our hypothesis that the osteoporotic-like phenotype observed after Pb exposure i

229 low strain rates reflects susceptibility for osteoporotic low-energy fragility fractures.

230 ime fractures in 154 patients, including 140 osteoporotic (low-energy trauma) fractures, of which 62%

231 low -1.00 to -2.00; moderate -2.01 to -2.49; osteoporotic <-2.5).

232 In men, the prevalence of these osteoporotic manifestations (46% <50 years; 73% >/=50 ye

233 levels are associated with a higher risk of osteoporotic manifestations.

234 urinary MH were independently related to the osteoporotic manifestations.

235 0.85; 95% CI: 0.72 to 0.99), and initiating osteoporotic medication (HR: 0.82; 95% CI: 0.71 to 0.95)

236 , muscle strength and insulin sensitivity in osteoporotic mice and humans.

237 s, as deletion of shn3 prevents bone loss in osteoporotic mice and short-term inhibition of shn3 in a

238 LD were applied to ovariectomy (OVX)-induced osteoporotic mice and the experiments were evaluated.

239 to regenerate critical-sized bone defects in osteoporotic mice by targeting Gsk-3beta to activate the

240 lly, systemic delivery of rAAV9-amiR-shn3 in osteoporotic mice counteracted bone loss and enhanced bo

241 Next, we demonstrated that osteoporotic mice exhibit atrophy of the periodontal lig

242 cells in culture and increased bone mass in osteoporotic mice in vivo.

243 city of PDL-derived osteoprogenitor cells in osteoporotic mice was associated with significantly slow

244 neral density and bone micro-architecture in osteoporotic mice.

245 In the ovariectomy (OVX)-induced osteoporotic mouse model, serum and bone marrow levels o

246 in the elderly, but the relationship between Osteoporotic (OP) and osteoarthritis (OA) is complex.

247 first-time, single-level vertebroplasty for osteoporotic or traumatic compression fractures were exa

248 Osteoporotic osteoarthritis (OPOA) is a common bone dise

249 For 3 years, 30 osteoporotic patients after LTX (28+/-6 months) were tre

250 s able to restore skeletal integrity in most osteoporotic patients and the long-term use of osteoporo

251 Bone marrow stem cells from osteoporotic patients are more likely to differentiate i

252 success of sclerostin antibodies in treating osteoporotic patients despite increased osteocyte-expres

253 Fitting implants in osteoporotic patients has traditionally been controversi

254 examine the risk of developing gallstone in osteoporotic patients in Taiwan.

255 We hypothesized osteoporotic patients might have higher risk in developi

256 reduced fracture risk in both osteopenic and osteoporotic patients, whereas bisphosphonates were asso

257 and subsequent management of postmenopausal osteoporotic patients.

258 strategy to promote bone tissue formation in osteoporotic patients.

259 Prevention of falls among frail, osteoporotic persons would likely reduce the frequency o

260 VIII deficient (FVIII(-/-)) mice develop an osteoporotic phenotype in the absence of induced hemarth

261 n to evaluate possible mechanisms whereby an osteoporotic phenotype might affect the rate of alveolar

262 Consistently, H2S-deficient mice display an osteoporotic phenotype that can be rescued by small mole

263 ingly, opg (AAA/AAA) mice displayed a severe osteoporotic phenotype that is very similar to opg-null

264 eocalcin-Cre;Hs2st (f/f) mice also displayed osteoporotic phenotype with similar severity to opg (AAA

265 t not VWF(-/-) mice, developmentally have an osteoporotic phenotype.

266 h osteoclast-specific Fbw7 ablation revealed osteoporotic phenotypes reminiscent of HCS, due to eleva

267 appendicular and jaw skeletons both develop osteoporotic phenotypes.

268 associated with increased bone resorption in osteoporotic post-menopausal women.

269 (99m)Tc-MDP plasma clearance (K(bone)) in 12 osteoporotic postmenopausal women (mean age, 67.3 y) bef

270 gested before recommendations for use in non-osteoporotic postmenopausal women with primary breast ca

271 of breast cancer in both high- and low-risk (osteoporotic) postmenopausal women.

272 Whereas, for anti-osteoporotic products and intestinal dysbiosis treatment

273 that several medications for bone density in osteoporotic range and/or preexisting hip or vertebral f

274 ge animal model, local delivery of NELL-1 to osteoporotic sheep spine leads to significant increase i

275 ifferentiated between healthy and osteopenic/osteoporotic states.

276 Osteoporotic subjects had worse ACH (odds ratio [OR] = 1

277 ent for age attenuated the association, with osteoporotic subjects having a 1.9-fold increase of bein

278 y, these results were corroborated in female osteoporotic subjects where we found decreased serum IL-

279 reas SERMS may be more effective when milder osteoporotic symptoms are present.

280 We randomized 63 non-osteoporotic, treatment-naive adult PWH initiating ART t

281 Intravertebral clefts occur frequently in osteoporotic VCFs of patients who present for vertebropl

282 9 [standard deviation]) with 422 symptomatic osteoporotic VCFs underwent 204 treatment sessions for o

283 and decreased analgesic use in patients with osteoporotic VCFs.

284 ease in severe, persistently mobile, clefted osteoporotic VCFs.

285 Background Osteoporotic vertebral compression fractures (OVCFs) are

286 ed 131 patients who had one to three painful osteoporotic vertebral compression fractures to undergo

287 of more than 2 million patients, those with osteoporotic vertebral compression fractures who underwe

288 broplasty is commonly used to treat painful, osteoporotic vertebral compression fractures.

289 values of patients with hyperkyphosis due to osteoporotic vertebral fracture were compared with those

290 y (SE) in patients with hyperkyphosis due to osteoporotic vertebral fracture.

291 rentiation of donors with from those without osteoporotic vertebral fractures at 3.0 T than at 1.5 T.

292 the effects of RANKL inhibitors on muscle in osteoporotic women and mice that either overexpress RANK

293 strozole-induced bone loss in osteopenic and osteoporotic women and might be offered in combination w

294 In postmenopausal osteoporotic women switching from teriparatide to denosu

295 ion study (DATA), in which 94 postmenopausal osteoporotic women were randomly assigned to receive 24

296 es in bone mineral density in postmenopausal osteoporotic women who transitioned between treatments.

297 ceiving risedronate (strata I and II) and in osteoporotic women who were all treated with risedronate

298 tion 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 year

299 ton absorptiometry (DPA) to demonstrate that osteoporotic women with vertebral fractures had lost sub

300 ity (estrogen-like effect) in postmenopausal osteoporotic women, but at the same time reduces the inc